Uso de fármacos antidepresivos en el tratamiento del síndrome de intestino irritable.

Saved in:

Bibliographic Details
Title:	Uso de fármacos antidepresivos en el tratamiento del síndrome de intestino irritable.
Alternate Title:	Use of antidepressant drugs in the treatment of irritable bowel syndrome.
Authors:	Cedeño Cedeño, Maylin Michelle¹ maylincede@gmail.com, Cedeño Moreira, Jeffry Freddy¹, Camacho Díaz, María José², Palma Chávez, Paola Elizabeth³, Moreira Marquinez, Silvia Patricia⁴, Falcones Espinoza, Andrea Michelle⁴, Bravo Véliz, Stephani Beatriz⁴, Moreira Alava, Rocke Alberto⁵, Ganchozo Mendoza, Adrián Alexander²
Source:	Archivos Venezolanos de Farmacología y Terapéutica. 2019, Vol. 38 Issue 6, p809-813. 5p.
Subjects:	SEROTONIN uptake inhibitors, MENTAL health services, IRRITABLE colon, TRICYCLIC antidepressants, ANTIDEPRESSANTS, PSYCHOLOGICAL factors, VISCERAL pain
Abstract (English):	The irritable bowel syndrome (IBS) is a highly frequent functional gastrointestinal disorder. A large part of the decrease in quality of life and the increase in economic burden associated with IBS stems from its widely variable nature, the multiplicity of available treatments, and the heterogeneity of the clinical results upon them. Current IBS therapy contemplates modifications in diet and physical activity, mental health care, and pharmacotherapy. The latter includes, among others, the use of antispasmodics, probiotics, antibiotics, and antidepressants (AD), especially selective serotonin reuptake inhibitors and tricyclic antidepressants. These are a particularly attractive alternative, as they may simultaneously manage the disease's psychological and physiological factors, such as those directly related with neurotransmission and intestinal local signaling. Although the theoretical foundation is rich, available clinical experience has highlighted the nuances and limitations of their use in practice. In the future, further research is needed to elucidate the ideal mode of prescription, as well as the specific AD with better balance between benefits and adverse effects, and the real relationship between the symptoms of IBS proper and depressive-anxious symptoms. Clarification of these aspects would serve as an invaluable orientation for the development of individualized treatment plans for each patient with IBS. This review explores current basic and clinical pharmacological aspects concerning the use of AD in the treatment of IBS. [ABSTRACT FROM AUTHOR]
Abstract (Spanish):	El síndrome de intestino irritable (SII) es un trastorno funcional gastrointestinal altamente frecuente. Gran parte del decremento en la calidad de vida y el incremento de la carga económica asociados al SII se deben a la naturaleza ampliamente variable de la enfermedad, la multiplicidad de tratamientos disponibles y la heterogeneidad de los resultados clínicos ante estos tratamientos. La terapia actual del SII contempla modificaciones en la dieta y la actividad física, atención en salud mental, y farmacoterapia. A su vez, ésta incluye, entre otros, el uso de antiespasmódicos, probióticos, antibióticos y antidepresivos (AD), especialmente los inhibidores selectivos de la recaptura de serotonina y los antidepresivos tricíclicos. Éstos constituyen una alternativa particularmente atractiva, en tanto podría abordar de manera simultánea los factores psicológicos de la enfermedad, así como factores fisiológicos directos relacionados con la neurotransmisión y señalización tisular intestinal. Si bien el fundamento fisiológico hipotético es muy rico, la experiencia clínica disponible ha resaltado los matices y limitaciones de uso en la práctica. En el futuro, se requiere mayor investigación para dilucidar el modo de prescripción idóneo, así como los agentes AD específicos con el mejor equilibrio entre beneficios y efectos adversos, y la relación real entre la sintomatología propia del SII y la sintomatología depresiva-ansiosa. La clarificación de estos aspectos serviría como una orientación invaluable en la confección de planes terapéuticos individualizados para cada uno de los pacientes con SII. En esta revisión se exploran los aspectos farmacológicos básicos y clínicos concernientes al uso de AD en el tratamiento del SII. [ABSTRACT FROM AUTHOR]
	Copyright of Archivos Venezolanos de Farmacología y Terapéutica is the property of Archivos Venezolanos de Farmacologia y Terapeutica and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	MedicLatina

Description
Abstract:	The irritable bowel syndrome (IBS) is a highly frequent functional gastrointestinal disorder. A large part of the decrease in quality of life and the increase in economic burden associated with IBS stems from its widely variable nature, the multiplicity of available treatments, and the heterogeneity of the clinical results upon them. Current IBS therapy contemplates modifications in diet and physical activity, mental health care, and pharmacotherapy. The latter includes, among others, the use of antispasmodics, probiotics, antibiotics, and antidepressants (AD), especially selective serotonin reuptake inhibitors and tricyclic antidepressants. These are a particularly attractive alternative, as they may simultaneously manage the disease's psychological and physiological factors, such as those directly related with neurotransmission and intestinal local signaling. Although the theoretical foundation is rich, available clinical experience has highlighted the nuances and limitations of their use in practice. In the future, further research is needed to elucidate the ideal mode of prescription, as well as the specific AD with better balance between benefits and adverse effects, and the real relationship between the symptoms of IBS proper and depressive-anxious symptoms. Clarification of these aspects would serve as an invaluable orientation for the development of individualized treatment plans for each patient with IBS. This review explores current basic and clinical pharmacological aspects concerning the use of AD in the treatment of IBS. [ABSTRACT FROM AUTHOR]
ISSN:	07980264